Apolipoprotein D expression in substantia nigra of Parkinson disease

被引:0
|
作者
Ordoñez, C
Navarro, A
Perez, C
Astudillo, A
Martínez, E
Tolivia, J
机构
[1] Univ Oviedo, Fac Biol & Med, Dept Morfol & Biol Celular, E-33006 Oviedo, Spain
[2] Hosp Cent Asturias, Serv Anat Pathol, Oviedo, Spain
关键词
apo D; dopaminergic neurons; glial cells; immunohistochemistry; neuromelanin;
D O I
暂无
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Apolipoprotein D (apo D), a lipocalin transporter of small hydrophobic molecules could play an important role in several neurodegenerative diseases. However, its role in those diseases remains unclear. Increments of apo D have been reported in relation with injury and degeneration in the nervous system. Recently increases of apo D level have been reported in schizophrenia, a neuropathologic disease where the oxidative stress and lipid abnormalities may be involved. Apo D could act as a sequestering molecule binding excess of arachidonic acid in cells. In order to determine the relationship between apo D expression and other neurodegenerative pathologies related to oxidative damage, we studied the presence of apo D in the substantia nigra of control and Parkinson disease (PD) subjects. We found dopaminergic neurons were not immunoreactive for apo D,. control or PD subjects. However, surrounding glial cells showed immunostaining for apo D and signal increases in PD cases. These findings support the role of apolipoprotein D in neuroprotection and the importance of glia in the amount of this protein in the central nervous system.
引用
收藏
页码:361 / 366
页数:6
相关论文
共 50 条
  • [1] α-synuclein expression in substantia nigra and cortex in Parkinson's disease
    Neystat, M
    Lynch, T
    Przedborski, S
    Kholodilov, N
    Rzhetskaya, M
    Burke, RE
    MOVEMENT DISORDERS, 1999, 14 (03) : 417 - 422
  • [3] α-Synuclein expression in Parkinson's disease and normal human substantia nigra
    Neystat, M
    Lynch, T
    Iverson, JA
    Rzhetskaya, MA
    Kholodilov, NG
    Przedborski, S
    Burke, RE
    NEUROLOGY, 1998, 50 (04) : A96 - A97
  • [4] Parkinson disease, substantia nigra vulnerability, and calbindin expression: Enlightening the darkness?
    Blesa, Javier
    Vila, Miquel
    MOVEMENT DISORDERS, 2019, 34 (02) : 161 - 163
  • [5] Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra
    Howells, DW
    Porritt, MJ
    Wong, JYF
    Batchelor, PE
    Kalnins, R
    Hughes, AJ
    Donnan, GA
    EXPERIMENTAL NEUROLOGY, 2000, 166 (01) : 127 - 135
  • [6] Hyperechogenicity of the substantia nigra in Parkinson's disease
    Ressner, Pavel
    Skoloudik, David
    Hlustik, Petr
    Kanovsky, Petr
    JOURNAL OF NEUROIMAGING, 2007, 17 (02) : 164 - 167
  • [7] Substantia nigra hyperechogenicity in Parkinson’s disease
    Edson Bor-Seng-Shu
    Erich Talamoni Fonoff
    Egberto Reis Barbosa
    Manoel Jacobsen Teixeira
    Acta Neurochirurgica, 2010, 152 : 2085 - 2087
  • [8] Ultrasonography of the substantia nigra in Parkinson's disease
    Ressner, P.
    Skoloudik, D.
    Kanovsky, P.
    MOVEMENT DISORDERS, 2006, 21 : S615 - S615
  • [9] Substantia nigra hyperechogenicity in Parkinson's disease
    Bor-Seng-Shu, Edson
    Fonoff, Erich Talamoni
    Barbosa, Egberto Reis
    Teixeira, Manoel Jacobsen
    ACTA NEUROCHIRURGICA, 2010, 152 (12) : 2085 - 2087
  • [10] Hyperechogenicity of the substantia nigra in Parkinson's disease
    Ressner, P
    Skoloudik, D
    Kanovsky, P
    NEUROLOGY, 2006, 66 (05) : A114 - A114